Myasthenia gravis is an autoimmune disease. The immune system produces antibodies that attack the connection point between nerves and muscles, disrupting the signals that tell muscles to contract. This causes the hallmark symptom of MG: muscle weakness that worsens with activity and improves with rest. It affects roughly 25 out of every 100,000 people, and its prevalence has been rising globally as populations age and diagnostic methods improve.
How the Immune System Attacks Muscles
In a healthy body, nerves communicate with muscles by releasing a chemical messenger called acetylcholine. This messenger crosses a tiny gap and lands on receptors sitting on the muscle surface, triggering the muscle to contract. In myasthenia gravis, the immune system creates antibodies that interfere with this process in three distinct ways: they physically block acetylcholine from reaching its receptor, they trigger the body’s own defense system to destroy the receptor entirely, or they cause the muscle cell to absorb and break down its own receptors faster than normal.
The end result is fewer working receptors on the muscle surface, which means the nerve’s signal gets weaker and weaker with repeated use. That’s why people with MG can often function well in the morning but struggle later in the day, or start an activity feeling fine only to fatigue rapidly. The muscles themselves are healthy. The problem is purely in the communication line between nerve and muscle.
The Antibodies Behind MG
About 85% of people with generalized MG have antibodies targeting the acetylcholine receptor directly. These are the most common and the easiest to detect with a standard blood test. Another 7 to 10% of all MG patients carry antibodies against a different protein called MuSK, which helps organize and maintain the receptor clusters on the muscle surface. MuSK-positive MG tends to look different clinically, with more pronounced difficulty swallowing, speaking, and breathing, and less of the drooping eyelids that typify other forms.
A smaller group, roughly 2 to 27% of patients who test negative for both of the above, have antibodies against a third protein called LRP4. These patients generally have milder symptoms and respond to standard treatments. That still leaves a subset of patients with no detectable antibodies at all, a condition called seronegative MG. Even in these cases, the disease is still considered autoimmune. The antibodies are likely present but at levels too low for current tests to reliably pick up, or they target proteins researchers haven’t identified yet.
The Thymus Gland’s Role
The thymus, a small organ behind the breastbone, plays a surprisingly central role in MG. Thymic abnormalities appear in about 80% of patients who carry acetylcholine receptor antibodies. In younger patients with early-onset MG, the thymus often shows a specific pattern called follicular hyperplasia, where immune cells form clusters that actively produce the very antibodies attacking the muscle receptors. The degree of this overgrowth correlates directly with antibody levels in the blood, and those levels drop after the thymus is removed.
The current model suggests a chain reaction inside the thymus: immune cells first encounter fragments of acetylcholine receptors on thymic tissue, become inappropriately activated, then recruit other immune cells to produce autoantibodies. Some patients also develop thymic tumors called thymomas, which create a similar immune environment that drives autoantibody production. Surgical removal of the thymus (thymectomy) has been shown to reduce steroid use, lower hospitalization rates for flare-ups, and decrease overall disease severity compared to medication alone. In one major trial, only 9% of patients who had thymectomy were hospitalized for MG exacerbations, compared to 37% of those on medication alone.
How MG Is Diagnosed
For patients with detectable antibodies, a blood test can confirm the diagnosis quickly. But for the roughly 50% of patients with purely ocular MG (affecting only the eyes) who test antibody-negative, diagnosis requires other tools. The two main electrical tests measure how well the nerve-to-muscle connection is functioning.
Repetitive nerve stimulation sends a series of electrical pulses to a nerve and records whether the muscle’s response fades with each successive pulse. Its sensitivity ranges widely, from as low as 10 to 17% in ocular MG to nearly 100% in generalized disease. Single-fiber electromyography is considerably more sensitive, detecting abnormalities in 82 to 99% of cases when two muscles are tested. It picks up subtle delays in the time it takes for a nerve signal to trigger a muscle fiber, a hallmark of the impaired transmission in MG. For seronegative patients, combining both tests along with a clinical picture that fits MG is the standard approach. Doctors may also repeat antibody testing after six months, since levels can fluctuate and become detectable over time.
From Ocular to Generalized MG
Many people first notice MG in their eyes: a drooping eyelid, double vision, or both. This is called ocular MG, and it can stay limited to the eyes indefinitely in some patients. But more than half of people who start with ocular symptoms will develop generalized weakness, typically within two years. “Generalized” means the disease has spread to affect muscles in the limbs, throat, or respiratory system. This progression isn’t inevitable, and early treatment with immune-suppressing medications may reduce the likelihood.
Myasthenic Crisis
The most dangerous complication of MG is myasthenic crisis, where the muscles responsible for breathing become too weak to maintain adequate airflow. The most common trigger is infection, particularly bacterial pneumonia or upper respiratory infections, which account for about 38% of crisis episodes. Other triggers include surgery, pregnancy, temperature extremes, physical or emotional stress, sleep deprivation, and certain medications like some antibiotics, beta-blockers, and calcium channel blockers. In roughly a third to half of cases, no obvious trigger is found.
Modern intensive care has transformed this from a frequently fatal event to a survivable one. Mortality from myasthenic crisis dropped from 42% in the early 1960s to around 4% today, with deaths now primarily related to other existing health conditions rather than the crisis itself.
How Treatment Targets the Immune System
Because MG is autoimmune, treatment works by either managing the symptoms at the muscle level or suppressing the immune attack itself. The first-line symptomatic treatment blocks the enzyme that normally breaks down acetylcholine, letting more of the chemical messenger accumulate and have a better chance of reaching the reduced number of receptors. This doesn’t fix the underlying problem but can meaningfully improve muscle strength.
For patients who need more than symptomatic relief, immune-suppressing medications reduce the production of harmful antibodies over time. During acute crises or severe flare-ups, treatments that rapidly remove antibodies from the bloodstream can provide faster relief. Thymectomy offers a more durable benefit for selected patients, particularly those under 65 with acetylcholine receptor antibodies and non-thymoma disease. In a randomized trial, 67% of thymectomy patients achieved minimal disease manifestations compared to 47% on medical therapy alone, and their need for additional immune-suppressing drugs dropped from 48% to 17%.
MuSK-positive patients tend to respond differently. They typically get less benefit from the standard enzyme-blocking medication but respond well to plasma exchange and other immune-targeting treatments. This difference in treatment response is one reason identifying the specific antibody type matters beyond just confirming the autoimmune diagnosis.